Hepatocellular carcinoma
Conditions
Interventions
TACE combined sorafenib group:TACE combined sorafenib
Sponsors
First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with histologically/cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treatment with TACE /TACE combined with sorefenib has been made. Radiographic diagnosis needs typical findings of HCC by radiographic method. i.e. on multi-dimensional dynamic CT, CT arterial portography (CTAP), CT hepatic arteriography or MR imaging; 2. Patients must have signed an informed consent; 3. Patients must have a life expectancy of at least 12 weeks; 4. The patients physician must be willing to compelet and submit all case report forms; 5. Physician must be documented medical records seriously.
Exclusion criteria
Exclusion criteria: 1. TACE criterion must be accordance with treatment guidance of HCC in China(2011 Edition), the indications must be under strict control; 2. Exclusion criteria must follow the approved product information of sorefenib (approved by CFDA of China).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| indocyanine green retention at 15 minutes; | — |
Countries
China
Contacts
Public ContactMing Xing Li
Outcome results
None listed